Abstract 5687: Development of glutathione pegylated liposomal doxorubicin (2B3-101) for the treatment of brain cancer

Pieter J. Gaillard, Olaf van Tellingen(Dutch Cancer Society), Chantal C.M. Appeldoorn, Werner Gladdines(BBB Therapeutics (Netherlands)), Jos H. Beijnen(The Netherlands Cancer Institute), Dieta Brandsma(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Willem Boogerd(The Netherlands Cancer Institute), Jaap Rip(BBB Therapeutics (Netherlands))
Cancer Research
April 1, 2012
10.1158/1538-7445.am2012-5687
Cited by 15

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884
Impairment of Cognitive Function in Women Receiving Adjuvant Treatment for High-Risk Breast Cancer: High-Dose Versus Standard-Dose Chemotherapy
|JNCI Journal of the National Cancer Institute|1998|768